Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1

In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854

Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research